Biolipox AB Reports Rapid Relief With NLA Nasal Spray In New Clinical Trial
10/19/2005 5:12:48 PM
STOCKHOLM, Sweden, Feb. 22, 2005 (PRIMEZONE) -- Biolipox, a Swedish research-intensive pharmaceutical company in respiratory and inflammatory diseases, announced today that it has successfully completed a new clinical study, evaluating the time-to-onset of effect of its new antihistamine treatment, NLA Nasal Spray. The drug was shown to have an onset of effect within 5-10 minutes after intake. This follows the announcement in June 2004 that NLA Nasal Spray had reached the primary efficacy endpoint of a Phase IIa study in patients suffering from allergic rhinitis. These results strongly support the development of NLA Nasal Spray as on-demand treatment.
comments powered by